TRILEPTAL is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Direct Rx. The primary component is Oxcarbazepine.
Product ID | 61919-569_33af9350-95f4-384e-e054-00144ff88e88 |
NDC | 61919-569 |
Product Type | Human Prescription Drug |
Proprietary Name | TRILEPTAL |
Generic Name | Oxcarbazepine |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2016-05-25 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA077802 |
Labeler Name | DIRECT RX |
Substance Name | OXCARBAZEPINE |
Active Ingredient Strength | 300 mg/1 |
Pharm Classes | Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE] |
NDC Exclude Flag | E |
Listing Certified Through | 2017-12-31 |
Marketing Start Date | 2016-05-25 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | ANDA |
Application Number | ANDA077802 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2016-05-25 |
Ingredient | Strength |
---|---|
OXCARBAZEPINE | 300 mg/1 |
SPL SET ID: | 33af9350-95f3-384e-e054-00144ff88e88 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0337 | Trileptal | oxcarbazepine |
0078-0357 | Trileptal | oxcarbazepine |
0078-0456 | Trileptal | oxcarbazepine |
0078-0457 | Trileptal | oxcarbazepine |
70518-1300 | Trileptal | Trileptal |
70518-1349 | Trileptal | Trileptal |
55289-007 | Trileptal | Trileptal |
61919-569 | TRILEPTAL | TRILEPTAL |
0054-0097 | Oxcarbazepine | Oxcarbazepine |
0054-0098 | Oxcarbazepine | Oxcarbazepine |
0054-0099 | Oxcarbazepine | Oxcarbazepine |
0054-0199 | Oxcarbazepine | Oxcarbazepine |
0615-6593 | Oxcarbazepine | Oxcarbazepine |
0615-6594 | Oxcarbazepine | Oxcarbazepine |
0615-6595 | Oxcarbazepine | Oxcarbazepine |
0615-8153 | Oxcarbazepine | Oxcarbazepine |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TRILEPTAL 74519619 2186101 Live/Registered |
Novartis Corporation 1994-05-02 |